CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.

Chen-Xing ZhaoZi-Xun YanJing-Jing WenDi FuPeng-Peng XuLi WangShu ChengJian-da HuWei-Li Zhao

Published in: Molecular cancer (2021)

CircEAF2 counteracted EBV + DLBCL progression via miR-BART19-3p/APC/β-catenin axis, referring circEAF2 as a potential prognostic biomarker. Therapeutic targeting EBV-encoded miRNA may be a promising strategy in treating EBV-associated lymphoid malignancies.

Keyphrases

epstein barr virus
diffuse large b cell lymphoma
cell proliferation
long non coding rna
long noncoding rna
epithelial mesenchymal transition
signaling pathway
drug delivery